FY2025 EPS Estimates for REGN Lowered by Cantor Fitzgerald

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for Regeneron Pharmaceuticals in a research report issued to clients and investors on Wednesday, February 5th. Cantor Fitzgerald analyst O. Brayer now expects that the biopharmaceutical company will post earnings per share of $29.37 for the year, down from their previous forecast of $38.93. Cantor Fitzgerald has a “Neutral” rating and a $1,015.00 price target on the stock. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $37.75 per share.

Other equities analysts have also issued research reports about the company. Bernstein Bank cut their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday. Evercore ISI cut their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Morgan Stanley decreased their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Canaccord Genuity Group started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Finally, Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Stock Down 1.7 %

REGN opened at $710.00 on Friday. The company has a fifty day moving average of $716.62 and a two-hundred day moving average of $913.59. The stock has a market capitalization of $78.02 billion, a price-to-earnings ratio of 17.57, a PEG ratio of 1.60 and a beta of 0.08. Regeneron Pharmaceuticals has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period in the previous year, the firm earned $11.86 EPS. The business’s quarterly revenue was up 10.3% on a year-over-year basis.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.50%. The ex-dividend date of this dividend is Thursday, February 20th.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the company. AGF Management Ltd. grew its stake in shares of Regeneron Pharmaceuticals by 281.2% in the 4th quarter. AGF Management Ltd. now owns 1,277 shares of the biopharmaceutical company’s stock valued at $910,000 after buying an additional 942 shares during the period. Wealthfront Advisers LLC lifted its holdings in Regeneron Pharmaceuticals by 68.5% in the fourth quarter. Wealthfront Advisers LLC now owns 15,990 shares of the biopharmaceutical company’s stock valued at $11,390,000 after acquiring an additional 6,501 shares during the last quarter. Cornerstone Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 31.7% in the fourth quarter. Cornerstone Advisors LLC now owns 7,900 shares of the biopharmaceutical company’s stock valued at $5,627,000 after acquiring an additional 1,900 shares during the last quarter. Mcdonald Capital Investors Inc. CA grew its position in Regeneron Pharmaceuticals by 24.7% in the fourth quarter. Mcdonald Capital Investors Inc. CA now owns 170,180 shares of the biopharmaceutical company’s stock worth $121,224,000 after acquiring an additional 33,727 shares during the period. Finally, Independent Advisor Alliance increased its stake in Regeneron Pharmaceuticals by 117.3% during the fourth quarter. Independent Advisor Alliance now owns 478 shares of the biopharmaceutical company’s stock worth $340,000 after acquiring an additional 258 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.